Sparfloxin is indicated for the treatment of adults (≥18 years of age) with the following infections caused by susceptible strains of the designated microorganisms:
- Community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae , or Streptococcus pneumoniae
- Acute bacterial exacerbations of chronic bronchitis (ABECB) caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus , or Streptococcus pneumoniae.
- Chronic Obstructive Pulmonary Disease (COPD)
- Acute Maxillary Sinusitis (AMS)
- Urinary tract infections including gonococcal and nongonococcal urethritis, chancroid and other sexually transmitted diseases.
- Bacterial prostatitis.
- Bacterial diarrhoea
- Osteomyelitis
- Other uses include treatment of tuberculosis in combination with rifampicin and isoniazid, treatment of leprosy in combination with standard drugs.